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INTRODUCTION 
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SYNAPSES 
 
The term synapse describes the specialized zone of functional contact between 
neurons, through which nerve cells can communicate with each others (Kandel, 
2013). 
The presynaptic neuron is the one that transmits signals, the postsynaptic neuron is 
the one that receives information. There are two different types of synapses: 
electrical and chemical. 
Chemical synapses are more abundant then electrical ones and convey the 
electrical signals indirectly via biochemical agents (neurotransmitters) whereas 
electrical synapses convey the electrical signal directly via ion channels (known as 
gap junctions). 
For this reason signal transduction occurs faster at electrical synapses but is much 
less modifiable compare to chemical synapses. 
In this study we will focus our attention on chemical synapses, so all of the following 
information refer to this type of synapses. 
Transmission across chemical synapses is mediated by two different  
neurotransmitters, that are glutamate in the excitatory synapses and γ-aminobutyric 
acid (GABA) in the inhibitory ones. 
 
EXCITATORY SYNAPSES 
 
Excitatory glutamatergic synapses represent the vast majority of the synapses 
involved in central neuronal communication.  
A typical characteristic of these synapses is the presence of a prominent post 
synaptic density (PSD), an electron dense thickening of the postsynaptic membrane, 
containing glutamate receptors, scaffold proteins, cytoscheletal molecules and signal 
transduction molecules (Sheng and Hoogenraad, 2007). On most principal neurons 
in the mammalian brain the PSD is localized on tiny actin rich protrusions, called 
dendritic spines (Sheng and Hoogenraad, 2007). Dendritic spines are small (0.5-2 
µm of length) motile protrusions that receive synaptic contacts from glutamate-
releasing axons. They contain all the essential postsynaptic components, including 
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the PSD, actin cytoskeleton and various membranous organelles such as the 
endoplasmic reticulum (ER) and endosomes. 
Typical mature spine has a bulbous head (receiving a single synapse) that is 
connected to the dendrite through a thin spine neck (Figure A) (Sheng and 
Hoogenraad, 2007). 
 
 
      
      Figure A: Microanatomy of dendritic spine 
Schematic representation of mature mushroom-shaped spine, in which are shown 
the PSD, the perysinaptic membrane and others organelles (Sheng and 
Hoogenraad, 2007). 
 
Due to its architecture and molecular organization, spine isolates the synapse from 
the rest of the dendrite creating in this way a microdomain as regards protein 
trafficking, ion release and downstream signaling. 
The number, size and shape of spines are subjected to plastic changes during 
development stages, allowing to long-term modification of synaptic strength (Sorra 
and Harris, 2000) (Sheng and Hoogenraad, 2007, Sheng and Kim, 2011). 
Spines shape has been categorized as “mushroom”, “thin” or “stubby” by Sheng 
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and Hoogenraad (Sheng and Hoogenraad, 2007), but in 2014 two others additional 
categories have been added: branched and cup-shaped spines (Ebrahimi and 
Okabe, 2014). The typical shape of a mature spine is the mushroom one, with a thin 
neck and a bulbous head (Sala et al., 2001). The shape, size and stability of spines 
depend on actin, that is the primary cytoskeleton within spines. There is a complex 
network of regulatory proteins, including Rho family GTPase, that control actin 
rearrangements (Tada and Sheng, 2006, Ethell and Pasquale, 2005). 
Several hundred proteins have been found at PSD; In particular PSD proteins are 
involved in cellular communication and signal transduction (adhesion, GTPases, 
kinase/phosphates, receptors, and channels), cellular organization (cytoskeleton, 
membrane traffic, motors, and scaffolds), energy (mitochondria and metabolism), 
protein synthesis and processing (translation and chaperones), and others (Figure 
B).  
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Figure B: Protein composition of the PSD fraction 
Chart showing the variety of proteins found in the PSD fraction of the forebrain, 
grouped according to cellular function. PSD proteins are involved in cellular 
communication and signal transduction, cellular organization, energy, protein 
synthesis and processing (Sheng and Hoogenraad, 2007). 
 
These membrane proteins are assembled into a disk-like proteinaceous structure, 
~300–400 nm wide and ~30–50 nm thick (Sheng and Hoogenraad, 2007). 
In addition to the PSD, the postsynaptic compartment also owns perysinaptic and 
extrasynaptic regions with highly specialized functions (Okabe, 2007, Harris and 
Weinberg, 2012) containing a distinctive set of proteins, such as metabotropic 
glutamate receptors (mGlu receptors) (Okabe, 2007, Harris and Weinberg, 2012), 
proteins involved in endocytosis and low levels of ionototropic glutamate receptors.  
 
 GLUTAMATE RECEPTORS 
 
Glutamate is the main excitatory neurotransmitter that can activates different types 
of glutamate receptors. 
Glutamate receptors can be classified in two groups depending on the mechanism 
by which their activation gives rise to a postsynaptic current. 
These two groups are: ionotropic receptors and metabotropic receptors. 
 
IONOTROPIC RECEPTORS 
 
Ionotropic receptors are non-selective cation channels that allow the passage of 
Na+, K+ and in some cases Ca2+, in response to their activation by glutamate; for this 
reason iGluRs mediates fast synaptic transmission. 
Depending on the selective agonist that activates iGluRs it is possible to group them 
in N-methyl-D-aspartate receptors (NMDARs), α-amino- 3-hydroxy-5-methyl-4-
isoazolepropionic acid receptors (AMPARs) and 2-carboxy-3-carboxymethyl-4-
isopropenylpyrrolidine (Kainate) receptors (KARs) (Kew and Kemp, 2005, Bigge, 
1999). 
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■NMDA receptors 
 
The NMDA subfamily of glutamate receptors forms multisubunit, nonselective cation 
channels similar to most other ligand-gated ion channel receptors (Kandel, 2013). 
NMDA receptors allow the entry of Ca2+ in addition to monovalent cations like Na+ 
and K+. 
This characteristic can produce an increase of the concentration of Ca2+ in the 
postsynaptic neuron and  the Ca2+ concentration change can then acts as a second 
messenger to activate intracellular signaling cascades (MacDermott et al., 1986). 
Other two unique properties of this class of receptors are that opening the channel 
requires the presence of a co-agonist (the amino acid glycine), and that extracellular 
Mg2+ acts as a voltage dependent ‘pore blocker’, blocking the channel at 
hyperpolarized, but not depolarized, voltages (Kandel, 2013). 
There are at least 7 different subunits of NMDA receptors: GluN1, GluN2A-D and 
GluN3A-B. Their activation requires the assembly of one obligatory GluN1 subunit 
and one of the GluN2 or GluN3 subunits (Okabe, 2007, Bigge, 1999, Kew and 
Kemp, 2005). 
NMDA receptors are ubiquitously distributed throughout the central nervous system 
(CNS). They are located mainly postsynaptically, but some of them are present on 
presynaptic membranes. 
 
■AMPA receptors 
 
AMPA receptors are widely expressed in the mammalian CNS and mediate fast 
excitatory neurotransmission in response to glutamate binding (Niciu et al., 2012) 
but their prolonged activation is highly neurotoxic (Szczurowska and Mareš, 2013). 
This class of receptors are homo- or heterotetramers composed of a four subunit 
family (GluA1–4 also called GluA-D) (Bigge, 1999). GluA2 subunit makes AMPARs 
not permeable to Ca2+ and drastically decreases their conductance, making the 
GluA2 a critical subunit for the regulation of synaptic AMPAR signaling (Bigge, 1999, 
Kew and Kemp, 2005). AMPA receptors different subunits are characterized by a 
transmembrane and an extracellular domains, that are very similar, indeed they 
differ only for the citoplasmatic intracellular tail. Thanks to the diversity of the 
intracellular tail each subunit of AMPARs interacts with different proteins. 
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The majority of the proteins that interact with AMPARs presents one or more PDZ 
domains, able to bind to the C-terminal intracellular tail of the AMPA subunits (Sala 
et al., 2001). 
The altered functions of AMPA receptors have been implicated in many neurological 
and psychiatric diseases, which make these receptors an attractive drug target 
(Cheng et al., 2012). 
 
■KAINATE RECEPTORS (KARs) 
 
This class of receptors is composed of two related subunit families, GluK1-5. They 
are tetrameric complexes that are widely expressed in the CNS and appear to be 
involved in the functioning of many neural networks. 
 
METABOTROPIC RECEPTORS 
 
In addition to causing a fast excitatory synaptic responses, glutamate has important 
neuromodulatory effects by the activation of G protein-coupled receptors (GPCRs) 
named metabotropic glutamate (mGlu) receptors (Chen et al., 2007). 
Like all G-protein coupled receptors, metabotropic glutamate receptors are seven 
transmembrane domains spanning receptors with an extracellular N-terminus and 
intracellular C-terminus (Niciu et al., 2012). 
This family of receptors includes eight subtypes termed mGlu1 to mGlu8 receptors, 
that are grouped in three different classes based on sequence homology, primary G 
protein coupling and pharmacological properties (Chen et al., 2007). 
These metabotropic receptors, which modulate postsynaptic ion channels indirectly, 
differ in their coupling to intracellular signal transduction pathways and in their 
sensitivity to pharmacological agents. 
 
■GROUP I 
 
All the members (mGluI and mGlu5) are coupled to Gq/11 G-proteins and are 
primarily localized to perisynaptic ring (Sheng and Hoogenraad, 2007) (Chen et al., 
2007). 
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mGlu5 receptors have a broad distribution within the CNS, with moderate to high 
expression levels in the cerebral cortex, dorsal and ventral striatum and 
hippocampus (Cleva and Olive, 2011), while mGlu1 is highly expressed in purkinje 
cells of the cerebellar cortex , in most of the thalamic nuclei, in the superior colliculus  
and in the hippocampus (Martin et al., 1992, Hubert et al., 2001). 
 
The stimulation of these receptors causes the activation of the associated enzyme 
phospholipase C, which hydrolyzes phosphoinositide phospholipids in the cell’s 
plasma membrane (Bonsi et al., 2005). As consequence inositol 1,4,5-trisphosphate 
(IP3) and diacyl glycerol are produced. Due to its hydrophilic character, IP3 reaches 
the endoplasmic reticulum, where it induces, by binding to its receptor, the opening 
of calcium channels increasing in this way the cytosolic calcium concentration (Chu 
and Hablitz, 2000, Bonsi et al., 2005, Bates et al., 2002). The lipophilic diacylglycerol 
remains in the membrane, acting as a cofactor for the activation of protein kinase C 
(Niciu et al., 2012). 
Activation of Group I mGlu receptors results in the activation of many intracellular 
signaling molecules such as protein kinase A (PKA), mitogen-activated protein 
kinase (MAPK), extracellular signal-related kinase (ERK), and cAMP response 
element binding protein (CREB) (Cleva and Olive, 2011). 
Interestingly, group I mGlu receptors are physically coupled to NMDA receptors 
through different proteins, including PSD-95, Shank, Homer, as well as through a 
direct interaction (Perroy et al., 2008). 
Group I of metabotropic receptors are also biochemically coupled to NMDA receptor 
function via PKC. 
So activation of these receptors causes an enhanced functionality of the NMDA 
receptors (Attucci et al., 2001, Rosenbrock et al., 2010). 
 
■GROUP II 
 
mGlu2 and 3 inhibit via Gi the adenylyl cyclase activity and are situated in 
presynaptic axon terminals where they modulate glutamate release (Cartmell and 
Schoepp, 2000, Thomas et al., 2001) 
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■GROUP III 
 
mGlu4, mGlu6, mGlu7 and mGlu8 combine with Gi and they are mainly localized at 
the axon terminals. 
 
Metabotropic glutamate (mGlu) receptors have been suggested to play a role in 
neuropsychiatric disorders including schizophrenia, drug abuse, and depression 
(Halberstadt et al., 2011). 
In addition, recently have been published different data reporting that rare genetic 
variation in the group I of metabotropic glutamate-receptor signaling pathway 
contributes to autism susceptibility (Kelleher et al., 2012). 
D’Antoni and colleagues reported that both an increased and reduced mGlu5 
functioning is related to ID and ASD (D'Antoni et al., 2014). 
For example the analysis of Fmr1-/Y mouse, a model of Fragile X, that is the most 
common inherited cause of autism, has shown excessive mGlu5-dependent synaptic 
protein synthesis and plasticity (Bear et al., 2004). 
On the contrary in several mouse models of tuberosclerosis syndrome (TSC), a 
genetic syndrome associated to ASD and ID, have been reported a decreased 
mGlu5 mediated LTD. 
Furthermore the association of mGlu5 alterations to ASD an ID is provided also by 
our previous in vitro data, in which we knocked down all the major Shank3 isoforms 
through RNA interference and we observed a dysfunctional mGlu5 mediated 
signaling. Our results suggest a possible role of mGlu5 signaling in the 
pathophysiology of Phelan McDermid Syndrome, that is a rare genetic disorder that 
causes a severe form of intellectual disability (ID), expressive language delays and 
other autistic features (Verpelli et al., 2011). 
 
Concluding many evidences underlie the involvement of group I of mGlu receptor 
signalling, in several disorders associated to ID and autism, suggesting that these 
receptors may be targeted by therapeutical interventions in different neuropsichiatric 
disorders (D'Antoni et al., 2014). 
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POSITIVE ALLOSTERIC MODULATORS (PAMs) OF mGlu5 RECEPTORS  
 
Positive allosteric modulators (PAMs) of mGlu5 receptors were developed to 
increase NMDA receptor function in order to ameliorate some cognitive deficits 
associated to schizophrenia, as there are some evidences that NMDA hypofunction 
causes cognitive problems in this disorder (Chen et al., 2007, Conn et al., 2009, 
Marino and Conn, 2002, Conn et al., 2008). 
Compare to PAMs, the classical orthosteric agonists of mGlu5, such as (S)-3,5-
dihydroxyphenylglycine (DHPG) and 2-chloro-5-hydroxyphenylglycine (CHPG) offer 
poor discrimination between receptors subtypes, because of the high degree of 
sequence homology of glutamate binding site, have poor brain barrier permeability 
and cause a rapid desensitization of the receptors (Cleva and Olive, 2011). 
On the contrary PAMs are able to bind the receptors at a different site and to 
increase their function in presence of the endogenous ligand (glutamate). 
One of the best characterized PAM is 3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-
yl)benzamide (CDPPB) and is the first one able to penetrate brain barrier. 
During the last years have been reported different studies demonstrating that  
CDPPB treatment is able to ameliorates cognitive deficits associated to different 
neuropsychiatric disorders (Cleva and Olive, 2011). 
In Tsc2 heterozygous mice, a model of of tuberosclerosis syndrome (TSC), a 
genetic syndrome associated to ASD and ID, the treatment with CDPPB is able to 
restore mGlu5 mediated LTD (Auerbach et al., 2011). 
In a mouse model lacking  exon 4-6 of SHANK2 gene, that presents ASD-like 
phenotypes, the treatment with CDPPB normalizes some behavioral deficits (Won et 
al., 2012). 
Finally, treating with CDPPB primary rat neurons knocked down for Shank3, we 
were able to rescue the altered mGlu5 mediated synaptic signalling (Verpelli et al., 
2011). 
Considering the therapeutic potential of PAMs to treat different neuropsychiatric 
disorders is not surprising that, at the moment different research groups are 
performing many studies to improve the pharmacological characteristics of these 
compounds. 
For example in 2015 have been identified VU0409551 as a novel mGlu5 PAM that 
exhibits distinct stimulus bias and selectively potentiates mGlu5 coupling to Gαq-
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mediated signaling but not mGlu5 modulation of NMDAR currents or NMDAR-
dependent synaptic plasticity (Rook et al., 2015). 
VU0361747, is another mGlu5 PAM optimized to eliminate allosteric agonist activity. 
It has robust in vivo efficacy and does not induce adverse effects at doses that yield 
high brain concentrations (Rook et al., 2013). 
 
Summarizing, the group I of mGlu receptors may represent a potential target for 
therapeutic interventions in some forms of neurodevelopmental disorders, such as 
ASD and the use of PAM could ameliorate different behavioral deficits associated to 
these disorders. 
 
SCAFFOLD PROTEINS 
Scaffolding component of the PSD represents a particular focus for the present 
study. This scaffolding component is characterized by proteins equipped with 
protein-protein interaction domains holding all molecules of the PSD and ensuring its 
assembly and functionality. One of the most important classes of scaffold proteins is 
the family of Shank proteins. 
 
SHANKs 
 
The ProSAP/Shank family of proteins contains three members all localized at the 
postsynaptic density level of excitatory synapses: Shank1 (Shank1a, Synamon or 
SSTRIP), ProSAP1/Shank2 (CortBP1) and ProSAP2/Shank3. 
The name ProSAP is due to the proline-rich clusters that are conserved among all 
the family members (Boeckers et al., 1999), the other term, Shank, was given by 
Naisbitt and colleagues (Naisbitt et al., 1999) and is referred to the SH3 domain and 
to the multiple ankyrin repeats present in this family of proteins.  
Shanks are large proteins with a molecular weight of more than 180KDa (Boeckers 
et al., 1999). 
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All the family members present different domains for specific protein-protein 
interactions and the presence of multiple domains within a single polypeptide is 
typical of scaffold proteins (Sheng and Kim, 2000). 
All Shank proteins contain from N-terminal to C-terminal, the following five well-
conserved domains: an N-terminal ankyrin repeats, an SH3 domain, a PDZ domain, 
a proline-rich domain, and a sterile alpha motif (SAM) domain (Figure C). 
 
 
Figure C: Shank protein domains structure 
Cartoon in which is shown the domain composition of Shank proteins. For each 
domain are listed the binding partners (Jiang and Ehlers, 2013). 
      
 -N-terminal ankirin domain (ANK) mediates the binding to α-Fodrin and Sharpin. 
α-Fodrin is one of the major constituent of the PSD and interacts with actin and with 
calmodulin. The interaction between ANK domain and α-Fodrin connects PSD to the 
cytoskeleton. 
Sharpin is a subunit of ubiquitin chain assembly complex, which is essential for the 
activation of Nf-kB signalling. Nf-kb is a transcription factor that is activated in 
synapses in response to excitatory synaptic transmission and plays an important 
role in different processes such as neuronal survival, memory and learning 
(Freudenthal et al., 2004). 
 
-Src homology 3 (SH3) domain modulates AMPA trafficking by binding GRIP, that is 
another scaffold protein, containing 7 PDZ domains interacting with AMPA receptors 
(Sheng and Kim, 2000). Moreover the SH3 domain also binds to the voltage-gated 
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L-type calcium channel CaV 1.3, this interaction is important to link calcium influx to 
pCREB signalling (Verpelli et al., 2012). 
 
-PDZ domain, binds the C-terminus of GKAP, which interacts with the guanylate 
kinase domain of PSD-95 via N-terminus, linking in this way Shank to NMDA 
receptor/PSD-95 complex (Sheng and Kim, 2000). 
PDZ domain interacts also with ProSAP-interacting protein 2 (ProSAPiP2), that is 
important in the attachment and modulation of cytoskeletal elements thanks to its 
actin binding characteristics. 
 
-proline rich region, contains  more than 1000 residues rich in proline and serine 
residues and commonly acting as binding sites for SH3 and EVH1 (Sheng and Kim, 
2000). 
The proline-rich region of Shank is able to mediate different sets of protein 
interactions; in particular two proteins have been shown to bind to the proline-rich 
region: Cortactin and Homer. 
Cortactin is an F-actin-binding protein enriched in the cell-matrix contact sites and in 
growth cones of neurons (Sheng and Kim, 2000). 
Cortactin moves to the cell periphery in a growth-factor and Rac-1 dependent 
manner and it redistributes to synapses in response to glutamate stimulation 
(Naisbitt et al., 1999). 
Thus Cortactin plays an important role in regulating the organization of actin 
cytoskeleton in the cell cortex and in dendritic spines. 
 
-SAM domain, is important for the localization of Shank proteins at the PSD. This 
domain allows self-multimerization via tail tail interaction, in particular  this self-
multimerization can be regulated by Zn2+ ions for Shank2 and 3 (Naisbitt et al., 1999, 
Gundelfinger et al., 2006, Grabrucker et al., 2011a). 
The Shank family members show a distinct pattern of expression: Shank1 is 
expressed almost exclusively in the brain; Shank2 is strongly expressed in the brain 
but is presents also in non-neuronal tissues, like kidney and liver. Shank3 is highly 
expressed in brain, heart and spleen (Sala et al., 2015). 
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All three family members are highly expressed in the hippocampus and cortex, 
whereas Shank3, but not Shank1 or Shank2, is highly expressed in the striatum 
(Verpelli et al., 2012). 
 
As mentioned above Shank proteins interact with different glutamate receptors. 
In this study we will focus on the interaction between Shank3 and the group I of 
metabotropic receptors, which includes mGlu5. 
The binding between mGlu5 and Shank3 is ensured by the association of the proline 
rich domain of Shank3 to another scaffold protein named Homer1. 
  
HOMER PROTEINS 
 
Homer proteins (Homer 1, 2, 3) are a family of scaffold proteins, that participate to 
different neuronal processes, ranging from calcium homeostasis to synaptic 
plasticity (Foa and Gasperini, 2009). 
They present an N-terminal enabled/vasodilator-stimulated phosphoprotein 
homology domain (EVH1) and a C-terminal coiled-coil (CC) domain. 
The EVH1 domain is involved in the binding to synaptic signalling ligands, such as 
the metabotropic glutamate receptor (mGlu), the inositol tri-phoshate (IP3R) and the 
ryanodyne receptors (RyR), and other scaffold proteins like Shanks. (Foa and 
Gasperini, 2009). Thus Homer physically and functionally links type I metabotropic 
glutamate receptors to their downstream effectors, the IP3 receptors, allowing a 
more efficient release of intracellular calcium in response to receptor stimulation 
(Sheng and Kim, 2000). 
Homer proteins posses a CC domain, which mediates homophilic and or heterophilic 
interactions with other members of the family. In particular Hayashi and colleagues 
in 2006 suggested that the native long-form Homers exist as tetrameric hubs with 
CC domains. The tetramerization exposes four EVH1 domains in a spatially 
optimized configuration for ligand binding that is required for efficient localization to 
dendritic spines. Thus Homer tetramers and antiparallel Shank homodimers can 
form multidimension scaffolding substrate through which ligands for both proteins 
can be efficiently assembled (Hayashi et al., 2006). 
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SHANK3 ISOFORMS 
In human and rodents SHANK genes present a very complex transcriptional 
regulation with multiple intragenic promoters and alternative spliced exons (Jiang 
and Ehlers, 2013). 
Trascripts of SHANK3 are the most and best characterized compare to the other two 
members of the family. 
Indeed in this gene the combination of multiple promoters and alternative splicing 
processes leads to a production of an extensive array of mRNA and protein isoforms 
that has not been fully characterized yet (Wang et al., 2014). 
The mouse SHANK3 gene presents 22 exons that encode a synaptic scaffolding 
protein with five functional domains. The alternatively spliced exons of SHANK3 
encode the SH3, proline-rich and SAM domains. 
SHANK3 contains at least five intragenic promoters both in humans and rodents, 
which produce specific isoforms (Shank3a-f, as described in Figure D) with a unique 
combination of different protein domains (Wang et al., 2014). 
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Figure D: Shank3 protein isoforms 
Diagram in which are shown SHANK3 protein isoforms (SHANK3 a-f).Protein 
domain structures were obtained from confirmed mRNA expressed from different 
promoters in human and mouse brains (Jiang and Ehlers, 2013). 
 
As described in detail above, each domain mediates specific protein-protein 
interactions so this could mean that each Shank3 isoform has a distinct set of 
functions. 
For example Shank3e and Shank3f mRNAs lack exon encoding the PDZ, that is 
necessary for the interaction between Shank3 and NMDA and AMPA receptors 
(Naisbitt et al., 1999). 
Shank3b is an isoform without the proline rich and SAM domains that are 
fundamental for Homer binding and  for multimerization (Tu et al., 1999). 
 
SHANKOPATHIES 
 
Considering the role of Shank proteins as master scaffolding molecules and their 
importance in regulating dynamic changes of synaptic morphology (Boeckers et al., 
2002) it's not surprising that all members of the SHANK gene family have been 
linked to human "synaptopathies". 
With this term are described  a group of neuropsychiatric disorders, which includes 
autism spectrum disorder (ASD), intellectual disability (ID), schizophrenia, obsessive 
compulsive disorder and bipolar disorder, so called because the mutations in these 
disorders lead to abnormal synaptic development or function (Han et al., 2013). 
Mutations and deletions in SHANK genes are so much involved in the generation of 
neurological disorders that has been coined a specific term to indicate diseases in 
which SHANK is impaired: the "Shankopathies".  
This definition includes different pathologies such as ASD, schizophrenia and 
Alzheimer disease. Within all ASDs, the most common Shankopathy is the Phelan 
McDermid Syndrome (PMS or 22q13.3 deletion syndrome) (Carbonetto, 2014). 
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PHELAN-MCDERMID SYNDROME 
 
Phelan-McDermid syndrome, also called PMS or 22q13.3 deletion syndrome, is a 
neurodevelopmental disorder, caused by a deletion in the terminal end of the long 
arm of chromosome 22. The size of the deletion leading to PMS can range from 
<100kb to >9Mb and these deletions cause the haploinsufficiency of four genes 
ACR, RABL2B, MGC70863 and SHANK3 (Guilmatre et al., 2014). 
The first evidence of the involvement of SHANK3 gene in the pathogenesis of PMS 
was reported in 2001 by Bonaglia and colleagues that identified a patient with a 
translocation between chromosome 12 and 22 (affecting only SHANK3), who 
presented the main symptoms of Phelan-McDermid Syndrome (Bonaglia et al., 
2001). In 2006 Wilson et al. found that 56 patients affected by PMS, presented a 
loss of 1 copy of SHANK3 gene (Wilson et al., 2003). After these two studies many 
others evidences documented that small deletions and mutations, that affect only 
SHANK3, caused similar phenotypes including ASD and ID (Durand et al., 2007, 
Boccuto et al., 2013). In addition de novo sequence changes including missense, 
frame shift and splice site mutations have been identified in SHANK3 gene of ASD 
patients (Dhar et al., 2010, Boccuto et al., 2013, Moessner et al., 2007, Uchino and 
Waga, 2013). 
 The genomic rearrangements identified in patients with PMS can range from simple 
22q13 deletions (72%), ring chromosomes (14%), unbalanced translocation (7%), to 
interstitial deletions, all resulting in haploinsufficiency of SHANK3 gene (Leblond et 
al., 2014). The unbalance translocation can be inherited or de novo, in 80-85% of 
individuals, or from others structural rearrangements involving chromosome 22, in 
15-20% of cases. Previous studies reported conflicting results from genotype-
phenotype correlations but now there are some new evidences that larger deletion 
sizes, which involved more genes, are associated with more severe phenotypes 
(Soorya et al., 2013, Dhar et al., 2010). 
The true incidence of PMS is unknown, and this is due to problems in diagnosis both 
at laboratory and clinical levels. 
The clinical features of PMS are heterogeneous, and no specific symptoms are 
considered pathognomonic, for this reason the diagnosis is based on genetic 
analysis (Costales and Kolevzon, 2015). 
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The identification of SHANK3 haploinsufficiency is performed using different genetic 
tests, the most common is CMA followed by multiplex ligation-dependent 
amplification to confirm the relative gene copy number (Schouten et al., 2002). 
The CMA analysis is not useful to identify the very small intragenic deletions (<30kb) 
and the mutations of the gene; in these cases DNA sequencing techniques, to 
evaluate individual base pairs within the gene, are required (Peters et al., 2015). 
Although PMS is characterized by heterogeneous clinical symptoms, the most 
common features of the syndrome include neonatal hypotonia, moderate to severe 
intellectual impairment, absent or delayed speech and normal growth (Phelan et al., 
2001). Developmental delays can’t appear during the first 12 months of life but a 
common symptom is the neonatal hypotonia that can contributes to poor feeding, 
weak cry, poor head control and delayed motor milestones, like crawling and walking 
(Phelan et al., 2001, Sarasua et al., 2014). 75% of patients affected by PMS shows 
language delays; in particular expressive language is more affected than receptive 
language (Phelan and McDermid, 2012). Differently to other autosomal chromosome 
abnormalities, that are associated with growth deficiency, patients affected by 
22q13.3 deletion syndrome have a normal range of growth. Different studies report a 
wide range of ASD prevalence in PMS (Bonaglia et al., 2001, Phelan et al., 2001, 
Sykes et al., 2009); in addition patients with PMS are commonly affected by ID, in 
particular 75% of individuals show severe-to-profound intellectual deficits (Soorya et 
al., 2013). Other common symptoms of PMS are various dysmorfic features such as 
ear abnormalities, bulbous nose, long eyelashes, large and fleshy hands, dysplastic 
toenails (Figure E). However the facial features most likely associated with deletion 
size, makes it difficult to diagnose this syndrome exclusively from the facial 
phenotype (Soorya et al., 2013, Costales and Kolevzon, 2015). 
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Figure E: Patients affected by PMS 
Patients affected by PMS show wide differences in facial phenotypes, that may 
create clinical diagnosis difficulties (Phelan and McDermid, 2012). 
 
PHELAN-MC DERMID TREATMENTS 
 
The only approaches to treat PMS at the moment are speech, occupational, physical 
and behavioral therapies. In addition the medical follow up is important to detect 
medical and psychiatric comorbidities. 
Only three clinical studies have been reported to treat PMS. 
The first one regards the use of intranasal insulin, which has been involved in 
synaptic plasticity in neuronal model and has ameliorated memory in patients 
affected by Alzheimer disease (Reger et al., 2009). In 6 patients treated 3 times daily 
for 12 months have been observed beneficial effects on cognitive function and motor 
development without adverse effects on glucose levels (Schmidt et al., 2009). 
The second clinical study regards the use of two second generation of 
antipsychotics, risperidone and more recently aripripazole, that have been approved 
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for symptomatic treatment of ASD. Both have been demonstrated to be effective in 
reducing maladaptive behaviors, e.g. irritability, that so often interfere with daily 
living activities and educational approaches (Canitano, 2014). 
The third possible approach is based on the use of Insulin-like growth factor 1(IGF-
1), a small polypeptide, that crosses the blood–brain barrier and is important in 
regulating synapse formation, neurotransmitter release and neuronal excitability via 
posttranslational modification of NMDA and AMPA receptors. The treatment of 
Shank3-deficient mice with IGF-1 improved AMPA receptor-mediated transmission, 
rescued cellular long-term potentiation and had beneficial effects on motor skills 
(Bozdagi et al., 2013). IGF-1 has been used also to treat pluripotent stem cells (iPS) 
derived from patients affected by PMS and resulted in improved NMDA- and AMPA-
mediated responses (Shcheglovitov et al., 2013). 
The first clinical study of IGF-1 administration in patients with PMS is currently 
underway, and preliminary results suggest tolerability and significant improvements 
in both social impairments and restrictive behaviors (Costales and Kolevzon, 2015). 
 
During these years the molecular mechanisms responsible for the deficits in PMS 
are becoming more understood and this will open new possibility to develop new 
strategy to treat patients affected by SHANK3 deletions and mutations. 
 
SHANK3 MOUSE MODELS 
 
Since little is known about the pathophysiological and molecular basis of ASD, the 
development of animal models is an important step towards a better understanding 
of human genetics of ASD and towards the discovery of effective therapeutic 
strategies. 
Mutant mice for all SHANK family genes have been produced, in particular seven 
Shank3 mutant mice have been reported (Peça et al., 2011, Schmeisser et al., 2012, 
Bozdagi et al., 2010, Wang et al., 2011, Kouser et al., 2013, Lee et al., 2015). 
Two different laboratories generated two mouse models with the deletion of exon 4-
9, lacking the ankyrin repeats: ∆ex4–9Buxbaum(A) (Bozdagi et al., 2010) and ∆ex4–
9Jiang (B) (Wang et al., 2011). Two mice were gererated by Peca and colleagues : one 
with the deletion of the exon 4-7 lacking the ankyrin repeats (Shank3 (4-7)) and one 
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with a deletion of exon 13-16 lacking the PDZ domain (Shank3 (13-16)) (Peça et al., 
2011).There are also a mouse with an exon 11 deletion lacking the SH3 domain 
(Shank3(11)) (Schmeisser et al., 2012), a mouse with an exon 21 deletion (Shank3 
(21)) lacking the major naturally occurring isoforms of Shank3 (Kouser et al., 2013) 
and finally a mouse with an exon 9 deletion lacking the ankyrin repeat region (Lee et 
al., 2015). 
All of the deletions in these mouse models cause a frame shift for targeted 
transcripts, generating a truncated Shank3 protein or possible disruption of full-
length RNA or protein isoforms due to the stability of encoded mRNA or protein. 
Considering that SHANK3 gene presents multiple intragenic promoters and 
alternative spliced exons, each of these mice is expected to have disruption of 
different Shank3 isoforms (Jiang and Ehlers, 2013, Sala et al., 2015). 
All the mouse models were characterized biochemically and behaviorally, and 
overall, the data obtained from the studies support a general conclusion that 
synaptic function is impaired and social behaviors are abnormal in mice with 
SHANK3 deletions. 
The major characteristics of each mouse model are reported in Figure F. 
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Figure F: Behavioral, molecular and electrophysiological characteristics of 
Shank3 mutant mice 
Cartoon in which are reported the main deficits of different Shank3 mutant mouse 
models (Sala et al., 2015). 
 
From the analyses performed on the different mouse models have been reported 
these main defects: repetitive and social behavior defects, memory and learning 
impairments. 
Repetitive behavior and generalized social deficits are typical phenotypes reported 
in ASD patients. Repetitive behavior in mice is represented by a self-grooming 
behavior. 
Increased self-grooming was found in both Shank3 (4-9)a and b mice (Bozdagi et 
al., 2010, Wang et al., 2011) and even more excessive grooming was observed in 
Shank3 (13-16) and Shank3 (11) mice (Peça et al., 2011, Schmeisser et al., 2012). 
No self-grooming was detected in Shank3 (4-7) mice and in Shank3 (9) mice that 
showed only a small increase in rearing behavior (Peça et al., 2011, Lee et al., 
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2015).These results suggest that different Shank3 isoforms may have different 
consequences in the expression of the self-grooming phenotype. 
Social deficits, which includes a broad range of impairments, such as interaction and 
communication have been analyzed in Shank3 mutant mice and the results show 
that all Shank3 mice, except for Shank3 (21), and Shank3 (9) mice, displayed 
reduced social interaction (Peça et al., 2011, Kouser et al., 2013, Bozdagi et al., 
2010, Wang et al., 2011). 
ASD is often associated with intellectual disability and, in humans, mutations in 
SHANK1-3 genes seems to have a gradient of severity in cognitive impairment 
(Leblond et al., 2014). 
The different Shank3 mice have different performances in learning and memory 
tests, suggesting again that each isoform of the protein plays different role in brain 
functions. 
Specifically, Shank3 (4-9)b and Shank3 (21) were significantly impaired in 
spatial learning measured by the “water maze test” (Kouser et al., 2013, Wang et al., 
2011) instead mild deficits were found in Shank3 (9) mice showing only a reduced 
number of exact platform crossings (Lee et al., 2015) and no defects were detected 
in Shank3 (13-16) and Shank3 (4-9)b (Peça et al., 2011, Wang et al., 2011); 
alterations in short-term and long-term memory were found only in Shank3 (4-9)b 
(Wang et al., 2011). 
From the molecular point of view Shank3 mice show a reduction of the glutamatergic 
synapses and Shank-associated scaffold protein except for Shank3 (11) mouse that 
showed a specific increase of GluN2B in the hippocampus and the Shank3 (21) 
mouse that presents a strong increase of mGlu5 in hippocampal synaptosome 
preparations (Sala et al., 2015). 
Summarizing at the moment we need more detailed studies to correlate phenotypes 
and molecular diversity in Shank3 mice. 
A simple hypothesis could be that the diversity of phenotypes in Shank3 mutant 
mice reflects the molecular diversity of Shank3 protein. 
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AIM OF THE STUDY 
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Shanks/ProSAPs (Shank1, Shank2/ProSAP1 and Shank3/ProSAP2) are a family of 
scaffold proteins, with a high molecular weight that have a crucial role in organizing 
the postsynaptic density (PSD) at the excitatory synapses. 
All Shanks proteins are characterized by multiple domains: N-terminal ankyrin 
repeats, an SH3 domain, a PDZ domain, a proline-rich domain, and a sterile alpha 
motif (SAM) domain. Through  these domains Shank proteins interact with a wide 
variety of different proteins within the PSD including other scaffold proteins, 
cytoskeletal proteins, signaling molecules and the three major classes of 
postsynaptic glutamate receptors, guaranteeing proper synaptic formation and 
function (Uchino and Waga, 2013). 
In particular the PDZ domain mediates the binding to AMPA receptors and through 
SAPAP the binding to PSD-95 and NMDA receptors and the proline rich domain is 
essential for the binding to Homer, another scaffold protein which binds to 
metabotropic receptors. 
Considering the importance of Shank proteins in proper establishment and 
maintenance of synaptic contacts and plasticity, is not surprising that mutations in 
the SHANK genes are strongly associated with autism spectrum disorders (ASD) 
and other neurodevelopmental and neuropsychiatric disorders, such as intellectual 
disability (ID), and schizophrenia (SCZ) (Grabrucker et al., 2011b). 
SHANK3 was the first gene in the SHANKs family reported to be associated with 
ASDs. 
SHANK3 genetic haploinsufficiency is the major cause of neuropsychiatric 
symptoms in 22q13.3 deletion syndrome (also known as Phelan-McDermid 
syndrome, (PMS)) (Uchino and Waga, 2013). Phelan-McDermid syndrome is a 
complex neurodevelopmental disorder resulting from the loss of the distal long arm 
of chromosome 22, in particular the q13.3 region. The size of the deleted segments 
varied widely in individuals with this syndrome, but deletions of SHANK3 were 
present in the majority of the cases (Dhar et al., 2010). 
PMS is characterized by neonatal hypotonia, global developmental delay, absent or 
severely delayed speech, autistic-like behaviors and intellectual disability. 
 
The aim of present work was to study the role of Shank3 in synapse formation and 
function and, in particular, to better understand the involvement of Shank3 on the 
major neurological features associated with PMS.  
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In our previous study we used RNAi to knockdown Shank3 expression in neuronal 
cultures and we demonstrated that the absence of Shank3 causes a reduction of the 
synaptic expression of metabotropic glutamate receptor 5 (mGlu5), and doesn’t 
affect the expression of other major synaptic proteins. 
As a functional consequence of Shank3 knock down we observed an impairment of 
mGlu5 mediated signaling. 
We augmented the activity of mGlu5 using a positive allosteric modulator named 3-
Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide, CDPPB and we found that this 
treatment was able to rescue, in vitro, mGlu5 mediated signaling (Verpelli et al., 
2011). 
In the present work we analyzed the behavioral phenotypes of Shank3∆11-/- mice 
which were generated by deleting exon 11, with the loss of the three major and 
higher MW isoforms of Shank3 protein. 
We found a significant increase of self-grooming activity and a reduction in 
sociability in KO mice. These data indicate that this mouse model presents repetitive 
behavior and impaired sociability, the two core symptoms of ASD. 
Starting from behavioral data and considering our previous results we decided to 
investigate the molecular mechanisms underlying the phenotypic deficits, analyzing 
in particular mGlu5 protein expression and signaling. 
We observed that, in striatum and cortex, the absence of Shank3 causes a reduction 
of mGlu5 and Homer1b/c proteins expression. 
Shank3 in these two specific brain regions plays an important role in mediating 
mGlu5 receptor signaling by recruiting Homer1b/c to the PSD. 
We enhanced the activity of mGlu5 receptor with a mGlu positive allosteric 
modulator, CDPPB and we found that the augmentation of receptor activity 
ameliorated the behavioral deficits observed in Shank3∆11-/-  mice. 
These results provide the rationale to use mGlu5 positive modulators as a possible 
pharmacological approach to treat patients affected by SHANK3 mutations and 
deletions. 
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MATERIALS AND METHODS 
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DNA CONSTRUCTS AND VECTORS 
 
For plasmid based RNA inhibition, Shank3 and luciferase oligonucleotides were 
annealed and inserted into the HindIII/BglII sites of the pLVTHM vector for lentivirus 
production of the shRNA. 
It was used the following siRNA sequence, that targets exon 21 of rat and mouse 
SHANK3 gene (GenBankTM accession number NM_021676 and NM_021423.3): 
5'–GGAAGTCACCAGAGGACAAGA–3'. The Shank3 rescue (Shank3R) construct, 
resistant to interference by siRNA, was generated by changing six nucleotides of the 
siRNA target site, without changing the amino acid sequence of the resultant protein 
(Verpelli et al., 2011). 
 
MICE 
 
The Shank3∆11-/- mice were kindly provided by Tobias M. Boeckers laboratory from 
Institute for Anatomy and Cell Biology, Ulm University, Germany as described by 
Schemeisser et al. 2012 (Schmeisser et al., 2012) and re-derived in a C57BL/6 
background (Charles River Laboratories, Calco, Italy). Mice were housed under 
constant temperature (22 ± 1°C) and humidity (50%) conditions with a 12 h light/dark 
cycle, and were provided with food and water ad libitum.  
Using heterozygous mice for breeding were obtained wild type and knockout 
littermates. 
All experiments involving animals followed protocols in accordance with the 
guidelines established by the European Communities Council and the Italian Ministry 
of Health (Rome, Italy). 
 
CELL CULTURE PREPARATION AND TRASFECTION OF PRIMARY RAT AND 
MOUSE CORTICAL NEURONS 
 
Low density rat cortical neuronal cultures were prepared from 18- to 19-day-old rat 
embryos as previously described with minor modifications (Verpelli et al., 2011) and 
were grown in 12-well Petri dishes (Primo). 
Mouse cortical neurons were obtained from E18 embryos, grown in 12- or 6-well 
petri dishes (Primo) and maintained in Neurobasal B27-supplemented medium (Life 
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Technologies). Rat cortical neurons were transfected using Lipofectamine 2000 on 
day 11 (DIV11), and the experiments were performed on DIV13-15. 
 
IMMUNOCYTOCHEMISTRY AND IMAGE ANALYSES 
 
Mouse cortical neurons were fixed at DIV13 in 100% methanol at -20°C for 10 
minutes. Rat cortical neurons were transfected at DIV 11 and fixed at DIV15 in 4% 
paraformaldehyde plus 4% sucrose at room temperature for 5 minutes; then neurons 
were washed 3 times (10 min for each wash) with PBS (136.8 mM NaCl, 2.68 mM 
KCl, 10.1 mM Na2HPO4 and 1.76 mM KH2PO4, pH 7.4 (all Sigma-Aldrich)). 
Primary antibodies (anti-Homer1, provided by Enjoom Kim Laboratory, KAIST 
Institute, Sout Korea and anti-Bassoon, Enzo Life Sciences, cat. ADI-VAM-PS003-F) 
and secondary antibodies were applied in GDB Buffer in PBS (30 mM phosphate 
buffer, pH 7.4, 0.2% gelatin, 0.5% Triton X-100, and 0.8 M NaCl).  
Mounted coverslips were imaged with a confocal (Zeiss 510 Confocal Microscope, a 
gift from Fondazione Monzino) with a 63× objective and sequential-acquisition 
setting at a resolution of 1024 × 1024 pixels.16 cortical rat transfected neurons for 
each construct, were chosen randomly for quantification from 4 to 10 coverslips from 
three independent experiments. A total of 16 neurons (cortical mouse neurons fixed 
at DIV 15) for each genotype (WT and KO) were randomly chosen for quantification 
from 4 to 10 coverslips from three independent experiments. 
Invastigators who where blind to the experimental conditions performed 
colocalization analyses. 
Colocalization measurements were performed using MetaMorph image analysis 
software (Molecular Devices, Downingtown, PA), by using color-separating Homer 
and Bassoon channels, manually setting a threshold level for each channel (identical 
for each neuron), and then determining the overlapping area. 
In graph, data are presented as SEM ± standard error. 
For the immunodetection of postsynaptic density markers on brain sections, the 
mice were anesthetized intraperitoneally using Avertin (Sigma-Aldrich) and then 
decapitated. The brains were rapidly excised and manually cut into coronal slabs 
that were fixed via immersion in ice-cold paraformaldehyde (4% in 0.1 M phosphate 
buffer, PB, pH 7.4) for 30 min (Giustetto et al., 1998). After fixation, the tissue slabs 
were rinsed in PBS, cryoprotected via immersion in ascending sucrose solutions 
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(10%, 20% and 30%), cut into 20-µm sections with a cryostat, mounted on gelatin-
coated slides and stored for a maximum of one month at −20°C until immunolabeling 
was performed. Following blocking in normal donkey serum (NDS, 3% in PBS with 
0.5% Triton X-100), the sections were incubated with primary antibodies diluted in 
PBS containing 3% NGS and 0.5% Triton X-100 overnight at 4°C (anti-PSD-95 
NeuroMab, Ca, USA cat. 75-028 and anti-Homer1 provided by Enjoom Kim 
Laboratory, KAIST Institute, Sout Korea). The sections were then washed and 
incubated with secondary antibodies that were diluted in 3% NGS and 0.5% Triton 
X-100 in PBS for 1 hour at room temperature. The sections were rinsed again and 
coverslipped with Dako fluorescence mounting medium (Dako Italia, Italy). For 
quantitative analysis of Homer1-immunoreactive puncta and colocalization studies, 5 
serial optical sections (using a 0.5-µm Z-step size) were acquired from sections 
including layers 2-3 of the primary somatosensory cortex (S1), the CA1 region of the 
hippocampus (stratum radiatum) and the dorsal striatum (caudate and putamen 
nuclei) using a laser scanning confocal microscope (LSM5 Pascal; Zeiss) with a 
100× objective (1.4 numerical aperture) and the pinhole set at 1 Airy unit. The 
density of the immunolabeled puncta was determined by manually counting 
postsynaptic clusters in neuropilar areas using dedicated software (Imaris, Bitplane, 
Zurich, CH) and expressed as puncta/100 µm2. 
 
SUBCELLULAR FRACTIONATION AND WESTERN BLOT ANALYSIS 
 
Subcellular fractionation of mice brain tissues was performed according to Distler et 
al. (Distler et al., 2014) with some modifications. 
Tissues were homogenized in buffer A containing 0.32 M sucrose and 5 mM HEPES 
(pH7.4) and centrifuged at 1.000 x g. The supernatant (S1) was further centrifuged 
at 12.000 x g, and a pellet containing the crude membrane fraction (P2) was 
obtained. This fraction was solubilized in buffer B containing 0.32 M sucrose and 5 
mM Tris (pH 8.1) and loaded onto a discontinuous sucrose step gradient (0.85 M/1.0 
M/1.2 M). After centrifugation at 85.000 x g, the synaptosomes were collected from 
the 1.0 M/1.2 M interface and incubated with buffer C containing 0.32 M sucrose, 12 
mM Tris (pH 8.1) and 1% Triton X-100. After centrifugation at 32.800 x g, the PSD 
pellet was collected and solubilized in H2O. 
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After protein exctraction, 10 ug of each sample were electrophoretically separated 
using SDS-PAGE and then blotted on nitrocellulose membranes according to 
standard protocols.  
Incubation with a primary antibody (β-actin Sigma, cat. A5316; Homer1b/c, 
SynapticSystems, cat. 160022,; mGluR5, Millipore, cat. AB5675; Shank3, Santa 
Cruz Biothecnology, cat. H-160; β3-tubulin, Covance, cat. PRB-435P) was followed 
by treatment of the membrane with HRP-conjugated secondary antibodies, and the 
signal was visualized using Pierce ECL Western Blotting Substrate and further 
detected using a MicroChemi 4.2 machine. All signals were quantified using Gel 
analyzer software (www.gelanalyzer.com/) and normalized against the values of the 
respective signal for β-actin or PSD-95. 
 
IMMUNOPRECIPITATION ASSAY 
 
PSD-enriched preparations (as described above) of different brain regions (cortex, 
hippocampus and striatum) from P60 WT and KO mice were incubated at 4°C 
overnight with protein A-Sepharose beads conjugated to rabbit Homer1b/c (10 µg/ml 
Santa Cruz cat. H-342) antibody and relative control IgG (10 µg/ml). The beads were 
then washed three times with Buffer C, re-suspended in sample buffer, warmed at 
65°C for 10 minutes and analyzed using SDS-PAGE. Western blot analysis was 
performed using mGlu5 (Millipore, cat. AB5675) primary antibody. 
 
FURA-2 SINGLE CELL Ca2+ IMAGING 
 
All measurements were carried out thanks to the collaboration with Department of 
Pharmaceutical Sciences, University of Eastern Piedmont “Amedeo Avogadro” 
(Novara, Italy) and analyses were kindly performed by Dr. Dmitry Lim. 
For Ca2+ measurements, 0.3 mln neurons were plated onto 24-mm round coverslips 
in 6-well plates. At DIV12-DIV14, the plates were loaded with 5 µM Fura-2 AM (Life 
Technologies, Milan, Italy) containing 0.002% Pluronic F-127 (Life Technologies) 
and 10 µM sulfinpyrazone (Sigma) in Krebs-Ringer modified buffer (KRB solution: 
125 mM NaCl, 5 mM KCl, 1 mM Na3PO4, 1 mM MgSO4, 2 mM CaCl2 5.5 mM 
glucose, and 20 mM HEPES, pH 7.4) for 30 min at room temperature (RT). The 
neurons were then washed twice in KRB, and the Fura-2 was allowed to de-esterify 
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for another 30 min at RT. The coverslips were then mounted in the acquisition 
chamber of a Leica DMI6000 epifluorescent microscope equipped with an S Fluor 
40x/1.3 objective. First, neurons expressing a GFP-tagged shShank3 or control 
(shCtrl) plasmid were imaged and photographed using Leica AM Meta Morph 
software (Molecular Devices, Sunnyvale, CA, US) at an excitation wavelength of 488 
with a bandpass 510-nm emission filter. The cells were then alternately excited at 
340 and 380 nm using a monochromator Policrome V (Till Photonics, Munich, 
Germany), and images of the fluorescent signals were captured each second 
through bandpass 510 nm filter using a CCD camera (Hamamatsu, Japan). All 
hardware was controlled, and Fura-2 images were analyzed using MetaFluor 
(Molecular Devices) software. To quantify differences in the amplitudes of Ca2+ 
transients, the ratio values were normalized using the formula (DF)/F0 (referred to as 
norm. ratio). To compare multiple samples (e.g., shShank3 and rescue results), 
ANOVA was used with Tukey’s post-hoc tests. To analyze differences between two 
samples (e.g., Shank3-KO results) Student’s two-tailed unpaired t-tests were used. 
Differences were considered statistically significant when p < 0.05.  
 
ELECTROPHYSIOLOGY 
 
All the experiments were carried out thanks to the collaboration with the University of 
Perugia and analyses were performed by Paolo Calabresi laboratory. 
Mice were sacrificed by cervical dislocation and coronal corticostriatal slices (250 
µm) were cut in Krebs’ solution (in mM: 126 NaCl, 2.5 KCl, 1.2 MgCl2, 1.2 NaH2PO4, 
2.4 CaCl2, 10 glucose, 25 NaHCO3) using a vibratome. The slices were maintained 
in Kreb's solution, bubbled with a O2 95% and CO2 5% gas mixture at room 
temperature (Calabresi et al., 1992). A single slice was transferred to a recording 
chamber and submerged in a continuously flowing Kreb’s solution (34°C, 2.5–3 
ml/min) bubbled with a 95 % O2–5 % CO2 gas mixture. Whole-cell patch-clamp 
recordings were obtained from dorsolateral striatal neurons optically detected 
(Olympus) and electrophysiologically identified as MSNs (Calabresi et al., 1992). 
Whole-cell voltage-clamp (Vhold -80 mV) or current-clamp recordings were 
performed with borosilicate glass pipettes (4–7 MΩ; Ra 15–30 MΩ) filled with a 
standard internal solution containing (in mM): 125 K+-gluconate, 0.1 CaCl2, 2 MgCl2, 
0.1 EGTA, 10 HEPES, adjusted to pH 7.3 with KOH. Signals were amplified with a 
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Multiclamp 700B amplifier (Molecular Devices), recorded and stored on PC using 
pClamp 10 (Molecular Devices). Membrane potentials and currents were recorded in 
the presence of 50 M picrotoxin to block GABAA receptors. Glutamatergic 
excitatory postsynaptic currents (EPSCs) were evoked by a bipolar electrode 
connected to a stimulation unit (Grass Telefactor) and located in the white matter 
between the cortex and the striatum. Paired-pulse ratios of EPSC amplitudes 
(EPSC2/EPSC1) were obtained by a paired-pulse stimulation protocol at 50 ms 
inter-stimulus interval.  
Drugs were bath-applied by switching the perfusion solution to drug-containing 
solution using a three-way tap syringe. Total replacement of the medium in the 
chamber occurred within 1 minute. CDPPB, CHPG, DHPG, NMDA, muscarine, 
picrotoxin, L-SOP, were purchased from Tocris-Cookson (Bristol, UK). CHPG, 
DHPG and muscarine were bath applied in the recording chamber alone and then 
co-applied with NMDA.  
Data analysis was performed off-line using Clampfit 10 (Molecular Devices) and 
GraphPad Prism 5 (GraphPad Software). Values in the text and figures are 
mean ± S.E., n representing the number of recorded neurons. Student’s t-test was 
used for statistical analysis with a significance level established at P<0.05.  
 
BEHAVIORAL ASSAYS 
 
For behavioral analyses, 3-month-old age-matched littermate mice were used. All 
tests were performed between 8 a.m. and 2 p.m. 
 
-Spontaneous motor activity  
Motor function was evaluated in an activity cage (43 × 43 × 32 cm) (Ugo Basile, 
Varese, Italy) that was placed in a sound-attenuating room as previously described 
(Sala et al., 2011). The cage was fitted with two horizontal and vertical infrared 
beams that were located 2 cm and 4 cm from the floor of the cage, respectively. 
Before the test each mouse was put in the testing room for 1 h. Cumulative 
horizontal and vertical movement counts were recorded for 10 min.  
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-Repetitive self-grooming 
Spontaneous repetitive self-grooming behavior was scored as previously described 
(McFarlane et al., 2008). Each mouse was placed into a standard cylinder, (46 cm 
length × 23.5 cm wide × 20 cm high).  
After a 10-min habituation period in the test cage, each mouse was scored with a 10 
min stopwatch for cumulative time spent grooming all body regions. The observer 
stayed at a distance of approximately 2 m from the test cage, and was blind to 
genotype while scoring self-grooming. 
-Spatial object recognition 
Object location tests were carried out in an arena according to Kenney et al. 
(Kenney et al., 2011), with minor modifications. Two visual cues were placed on two 
adjacent walls of an opaque white Plexiglas cage (58×50×43 cm) that was dimly lit 
from above (27 lux). The visual cues consisted of a black and white striped pattern 
(21×19.5 cm) that was affixed to the center of the northern wall and a black and gray 
checkered pattern (26.5×20 cm) that was placed in the center of the western wall. 
The objects were counterbalanced across locations. The cage and the objects were 
thoroughly wiped down with acetic acid (0.1%) before and after all behavioral 
procedures, which were observed and recorded using a camera mounted above the 
cage. Climbing or sitting on objects was not scored as object exploration. Mice that 
did not spend more than a total of 30 s exploring the objects during training or 
testing were excluded from the analysis. Mice were pre-exposed to the cage for 10 
min. Twenty-four hours later, the mice were returned to the cage and allowed to 
explore two different objects placed in the NE and NW corners, and the time spent 
exploring the objects was recorded. Two hours later, the object the mouse had spent 
more time exploring in the previous session was moved to the SW corner of the 
cage (only this object was placed in the cage), and the mouse was allowed to re-
explore the cage. Exploration was defined as a mouse having its nose directed 
toward the object and within approximately 1 cm of the object(Bevins and Besheer, 
2006). Performance was evaluated by calculating a discrimination index (N-F/N+F), 
where N = the time spent exploring the moved object during T2, and F = the time 
spent exploring the stationary object during T2. 
-Sociability and Preference for Social Novelty Tests 
The apparatus was a rectangular, three-chamber, transparent polycarbonate box 
(width = 42.5 cm, height = 22.2 cm, center chamber length = 17.8 cm, and side 
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chamber lengths = 19.1 cm) as previously described 27. The test mouse was first 
placed in the middle compartment, and it was allowed to explore all three chambers 
for 10 min (habituation). Then, an unfamiliar adult DBA/2J male mouse was placed 
in one side compartment. The opposite side compartment contained an empty wire 
cage. The social novelty tests were performed in the same apparatus immediately 
after sociability test. The cages were not cleaned between these two tests. For these 
tests, one side compartment contained the familiar mouse (from the previous 
sociability phase), while the other side contained an unfamiliar mouse. The new, 
unfamiliar mouse was placed in the wire cage that had been empty during the prior 
10-min session. The familiar and unfamiliar animals were from different home cages 
and had never been in physical contact with the subject mouse or with each other. 
For both tests, the time spent in each chamber and the number of entries into each 
chamber were recorded for 10 min. The data were expressed as the difference in 
the scores between the time spent exploring the compartment containing the familiar 
mouse and the time spent in the empty compartment (for sociability tests) or the 
difference in the scores between the time spent containing the stranger animal and 
the time spent with the familiar mouse (for social novelty tests). An operator blind to 
the genotypes of the mice manually recorded the time spent in each chamber. We 
also evaluated a sociability index (SI) and a social novelty preference index (SNI) as 
follows: SI = (time exploring novel mouse 1 – time exploring novel object) / (time 
exploring novel mouse 1 + time exploring novel object) and SNI = (time exploring 
novel mouse 2 – time exploring familiar mouse) / (time exploring novel mouse 2 + 
time exploring familiar mouse). 
-Morris water maze test 
The Morris water maze test was adapted fro mice and used to analyze changes in 
the learning and memory abilities of the mice according to the methods described in 
Morris (Morris, 1984). A circular water maze (120 cm in diameter x 50 cm in height) 
was used. A circular hidden platform with a diameter of 10 cm was placed inside the 
maze, and its surface was maintained at 0.5 cm below the surface of the water. 
Floating plastic particles were placed on the surface of the water to hide the platform 
from sight according to the methods of Zhang (Zhang et al., 2013). The temperature 
of the water was 25.0°C ± 0.5°C. For the habituation trials, the mice were placed in a 
random area inside the maze and allowed to swim for 60 sec. For the acquisition 
trials, the mice were submitted to 4 trials per day (with 60 sec inter-trial intervals) for 
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4 consecutive days during which each mouse was released into the pool at different 
starting points and trained to locate a constant platform position. At 24 hours after 
the last trial, a probe test was performed during which the platform was removed. 
Two days later, a reversal task was performed to assess cognitive flexibility. The 
platform was placed in the opposite quadrant of the tank, and 4 daily trials were 
performed for 4 days. On the fifth day, a probe trial was performed that was similar 
to that in the acquisition phase. The time spent in the target area and the latency to 
reaching the target zone were evaluated by an experimenter who was blind to the 
genotypes of the mice. After each trial, the mice were placed on a paper towel to 
dry, and they were then placed back into their home cages. 
-T-maze test  
Mice were deprived of food until they reached 85–90% of their free-feeding body 
weight. They were habituated to a black wooden T-maze (with a 41-cm stem section 
and a 91-cm arms section). Each section was 11 cm wide and had walls that were 
19 cm high. The mice were habituated to the T-maze and trained to obtain food 
within the maze for 5 days as previously described (Sala et al., 2011) .During the 
acquisition phase, one arm was designated the reinforcer (Coco Pops; Kellogg’s) in 
each of ten daily trials. Each mouse was placed at the start of the maze and allowed 
to freely choose which arm to enter. The number of days required to reach the goal 
criterion (80% correct for 3 days) was recorded. Each mouse that met the goal for 
acquisition was then tested using a reversal procedure in which the reinforcer was 
switched to the opposite arm. 
 
PHARMACOLOGICAL TREATMENTS 
 
CDPPB (Tocris) was resuspended in DMSO and polyethylene glycol 400 
(DMSO:PEG 400 = 1:9). 70 min before each behavioral test. Wild-type and 
Shank3∆11-/- mice were injected intraperitoneally with CDPPB (3 mg/kg) containing 
solution or the same volume of a DSMO:PEG400 mixture. 
 
iPSC GENERATION AND DIFFERENTIATION INTO NEURONS 
 
Patients diagnosed with Phelan-McDermid syndrome, using genetic analysis, were 
involved in this study. 
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Fibroblast from patients and healty donors were collected according to a clinical 
protocol approved by the local Bioethical Committees of different medical centers. 
All the individuals involved in the study were informed of the objectives of the study and 
were required to sign an informed consent document before inclusion into the study. 
The generation, maintaining and characterization of iPS cells were performed as 
described by Verpelli et al, 2013 (Verpelli et al., 2013). 
These primary antibodies were used for immunofluorescence analysis on iPs cells and 
differentiated neurons: Nanog (Abcam cat. AB80892), Oct3/4 (Santa Cruz 
Biotechnology cat. sc-5279), Sox2 (Proteintech cat. 11064-1-AP), MAP2 (Abcam cat. 
AB11268), Synaptophysin (Sigma MS5768). 
 
STATISTICS 
 
All quantitative biochemical data are representative of three independent experiments, 
and all behavioral data are representative of at least two experiments. 
Unpaired two-tailed t-test was used to evaluate the difference between two groups. The 
variances in two groups were similar in all data sets. Two-way analysis of variance 
followed by post hoc test was used for comparison of multiple samples. Significance 
was set at P<0.05. All values are presented as mean ± SEM. 
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Deletion of Exon 11 of SHANK3 gene causes ASD-like behaviors in mice 
 
To clarify if a SHANK3 mutation in mice causes ASD-like behaviors and intellectual 
disability we characterized the behavior of Shank3∆11-/- mice, previously generated 
deleting the exon 11 of the SHANK3 gene (Schmeisser et al., 2012). 
ASD includes various neurodevelopmental disorders, characterized by two 
behavioral domains:  repetitive/stereotypic behaviors and impaired social interaction. 
All the behavioral experiments were performed in collaboration with Prof. Maria 
Elvina Sala. 
As a measure of repetitive behavior we analyzed grooming behavior; Shank3∆11-/- 
mice present an increased self-grooming activity in terms of time spent grooming 
and number of grooming episodes (Figure 1A). 
The second core symptom of ASD is the impairment of social interaction; for this 
reason we tested Shank3∆11-/- mice for sociability using the three chambers test 
(Figure 1B). 
KO mice spent more time exploring the compartment with the empty cage than the 
one with the stranger mouse (Figure 1B left) and remained closer to the family 
stranger for longer time, suggesting an impairment in sociability and social 
recognition (Figure 1B right). 
Accordingly, the corresponding sociability index (SI) and social novelty preference 
index (SNI) scores were lower in KO mice than their WT littermates. 
Mutations in SHANK3 gene are associated with intellectual disability, for this reason 
we tested spatial learning and memory of KO mice. 
To evaluate spatial memory, we used a spatial object recognition test in which we 
analyzed a discrimination index with an inter-trial interval of 120 min. We did not 
detect significant differences between WT and KO mice (Figure 1C). 
We also tested mice with Morris Water maze test and we found that KO mice 
showed normal acquisition compared to WT littermates (Figure 1D left). Spatial 
memory was then tested using a probe trial, which was administered after a 4-day 
training period during which we measured the latency (Figure 1D, center) and the 
time required to reach the target quadrant (Figure 1D, right). We did not detect any 
significant difference between the genotypes. The latency and the percentage of 
time spent swimming to the target quadrant were also not significantly different. On 
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the contrary, the escape latency of KO mice was longer than the latency in WT mice 
on day 8 and day 9 (Figure1E, left). In the probe trial, the KO mice took longer to 
find the target zone (Figure 1E, center) and spent less time than WT mice to swim 
to the quadrant that previously housed the platform (Figure1E, right). 
Shank3∆11-/- mice also showed impairments in the T-maze task, but only during the 
reversal phase (Figure1F). KO mice required more days to achieve the criterion 
than WT mice. These results indicate that KO mice show a resistance in changing a 
learned pattern of behaviors, suggesting a cognitive rigidity. 
Taken together our behavioral data demonstrate that Shank3∆11-/- is a good mouse 
model to clarify the role of Shank3 in PMS because this mutant line shows the main 
behavioral features associated to PMS. 
 
Shank3 absence alters Homer and mGlu5 synaptic localization 
 
Shank3 is a multidomain protein localized at the PSD of glutamatergic synapses 
where it acts as a major scaffold protein interacting directly or indirectly with all types 
of glutamate receptors and cytoskeletal elements via different domains. 
In particular the association between Shank3 and type I of metabotropic receptors, 
which includes mGlu5, is ensured by the interaction between Homer1 and the 
proline rich domain of Shank3. 
In our previous work we demonstrated that knock-down of Shank3, using a shRNA 
technique, in primary neurons causes a significant reduction of mGlu5 protein 
expression (Verpelli et al., 2011). 
Based on these results we decided to measure mGlu5 and Homer1b/c protein levels 
in the PSD fraction of striatum, cortex and hippocampus of Shank3∆11-/- mice 
(Figure 2A). We found a reduction of Homer1b/c protein levels in striatum (Figure 
2A left), a reduction of both mGlu5 and Homer1b/c in cortex (Figure 2A center) and 
non change in mGlu5 and Homer1b/c in hippocampus (Figure 2A right). 
This biochemical analysis indicates that the absence of Shank3 alters, in vivo, 
mGlu5 and Homer1b/c protein expression specifically in the PSD of two brain 
regions, cortex and striatum. 
To understand whether the localization of Homer was altered in absence of Shank3, 
we next analyzed postsynaptic Homer1 localization in the dorsal striatum, in layers 
42 
 
2-3 of the primary somatosensory cortex and in the CA1 stratum radiatum of the 
hippocampus in Shank3∆11-/- mice using immunofluorescence and confocal 
microscopy (Figure 2B). 
From this analysis we found that the total density of Homer1-positive puncta is 
unchanged between WT and KO mice in all the brain regions (Figure 2B). 
KO mice showed an increase of Homer1 puncta not colocalizing with PSD-95 and in 
parallel, a significant reduction of double-labeled puncta both in dorsal striatum and 
in somatosensory cortex (Figure 2B). We did not observe any changes in Homer1 
localization in the CA1 area of hippocampus in this analysis too (Figure 2B). 
To understand if this alteration in the synaptic localization of Homer1 causes a 
reduction of the interaction between Homer and mGlu5 we co-immunoprecipitated 
both proteins in striatum, cortex and hippocampus of WT and KO mice (Figure 2C). 
Western blot analysis revealed a significant reduction of mGlu5 and Homer1b/c 
protein-protein interaction in both striatum and cortex but not in hippocampus of 
Shank3∆11-/- mice compared to WT littermates (Figure 2C). 
From our biochemicall and immunoistochemical studies we can conclude that the 
absence of Shank3 causes brain-specific alteration of both protein expression and 
localization of mGlu5 and Homer1b/c at synapses, preventing in this way the correct 
formation of mGlu5/Homer complex, which is essential to mediate mGlu5 
intracellular signaling. 
 
Shank3 absence impairs mGlu5-mediated intracellular calcium release 
 
mGlu5 receptor is a metabotropic receptor coupled to Gq/G11 G-protein. The 
stimulation of the receptor causes the activation of phospholipase C (PLC), a Ca2+-
dependent enzyme that catalyzes the hydrolysis of phosphatidylinositol 4,5 
bisphosphate (PIP2) to yield inositol 1,4,5 trisphosphate (IP3) and diacylglycerol 
(DAG), which are important cellular second messengers. In particular IP3, binding to 
IP3 receptors, causes an increase of calcium release from intracellular stores 
resulting in cell depolarization, enhanced cell excitability, and activation of numerous 
intracellular signaling molecules such as protein kinase A (PKA), protein kinase C 
(PKC), mitogen-activated protein kinase (MAPK), extracellular signal related kinase 
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(ERK), and cAMP response element binding protein (CREB) (Cleva and Olive, 
2011). 
Interestingly Homer protein, thanks to its EVH1 domain, is able to bind both mGlu5 
receptor and the inositol tri-phosphate (IP3) receptors. Thus Homer physically and 
functionally links mGlu5 receptors to their downstream effectors, the IP3 receptors, 
allowing a more efficient release of intracellular calcium in response to receptor 
stimulation (Sheng and Kim, 2000). 
Considering that we found alterations in Homer and mGlu5 synaptic expression, 
interaction and localization in Shank3∆11-/- mice, we investigated if the absence of 
Shank3 altered the generation of mGlu5-mediated Ca2+ signals,  using cortical 
neurons obtained from Shank3∆11-/- mice. 
First, we confirmed that the reduction of the mGlu5 receptor and Homer1b/c protein 
levels that was observed in the cortex was also observed in the synaptic fractions of 
cultured cortical neurons obtained from Shank3∆11-/- mice (Figure 3A). Then, we 
measured the induction of Ca2+ transients by 200 µM DHPG ((S)-3,5-
Dihydroxyphenylglycine), a specific group I metabotropic receptor agonist. Figure 
3B shows that DHPG-induced Ca2+ transients in KO neurons were significantly 
lower than in WT neurons, indicating that the absence of the Shank3 protein 
impaired mGlu5-mediated signaling in cortical neurons.  
To confirm that these alterations in calcium signaling mediated by mGlu5 receptor 
activation were due to alterations in the synaptic localization of Homer, we analyzed 
the synaptic distribution of Homer1b/c using immunofluorescence in cultured cortical 
neurons that were derived from Shank3∆11-/- and WT mice. Quantification of the co-
localization of Homer puncta and Bassoon (a presynaptic marker) revealed that the 
postsynaptic localization of Homer was reduced in the Shank3∆11-/- cortical cultured 
neurons (Figure 3C).  
Verpelli et al. (Verpelli et al., 2011) previous demonstrated that in vitro, the reduction 
of mGlu5 receptor activity that was caused by Shank3 knock-down could be rescued 
using an allosteric mGlu5 positive modulator CDPPB.  
For this reason we tried to rescue deficits in mGlu5-mediated Ca2+ signals using 
CDPPB in cortical neurons obtained from KO mice. 
In these experiments, DIV12-14 cortical neuronal cultures were loaded with Fura-2 
and challenged with 200 µM DHPG in either the presence (5 min of preincubation) 
or the absence of 3 µM CDPPB (Figure 3D). As expected, in the Shank3∆11-/- 
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cortical neurons, the DHPG-induced Ca2+ transients were approximately 40% lower 
than in the WT neurons. After preincubation with CDPPB, the Ca2+ transients in the 
Shank3∆11-/- neurons were significantly augmented, reaching the level of WT 
neurons (Figure 3D). 
In addition to these we performed other experiments, in which we knocked down 
Shank3 using specific shRNA sequences. 
Figures 3E and G show that the administration of 200 µM DHPG elicited a much 
lower Ca2+ transient in shRNA-Shank3-tranfected neurons than in control neurons 
(either non-transfected or transfected with a GFP-expressing plasmid). When the 
shShank3-resistant form of Shank3 was co-expressed with the shRNA-Shank3 
plasmid, the DHPG-induced Ca2+ transients were restored to control levels, 
indicating that the effect of shRNA-Shank3 transfection was specific. We confirmed 
using immunofluorescence that Homer-Bassoon co-localization was altered also in 
Shank3 knock-down neurons (Figure 3F). 
These sets of experiments demonstrates that the absence of Shank3, in vitro, 
causes an impairment of mGlu5-mediated Ca2+ release that can be restored by the 
application of CDPPB, a positive mGlu5 receptor allosteric modulator. 
 
The effect of mGlu5 stimulation on NMDA responses in striatal medium spiny 
neurons is dependent on Shank3 
 
Because we observed, in striatum, a disruption in synaptic Homer localization in the 
absence of Shank3, we tested the electrophysiological properties of striatal neurons. 
Patch-clamp recordings were measured using medium spiny neurons (MSNs) 
obtained from WT and KO mice to explore whether the deletion of Shank3 affected 
the basal membrane properties of striatal neurons. Current-voltage curves were 
obtained by delivering hyperpolarizing and depolarizing steps of currents to the 
MSNs of KO (n=6) and WT (n=6) mice, and we observed no difference between 
these two groups of neurons, suggesting that the basal membrane properties of 
MSNs do not depend on Shank3 expression (Figure 4A-B).  
We subsequently studied whether Shank3 was responsible for the observed 
changes in the membrane potential and the ionic currents induced by the stimulation 
of group I mGlu receptors in MSNs. Activation of these types of metabotropic 
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glutamate receptors has been shown to enhance the membrane 
depolarization/inward current that is produced by the activation of the NMDA 
receptor in striatal MSNs (Pisani et al., 2001). As shown in Figures 4C and 4G, the 
application of 30 µM NMDA produced a membrane depolarization of approximately 
15 mV and an inward current of approximately -70 pA in MSNs in WT mice, while 
the co-application of NMDA in the presence of DHPG produced a significantly larger 
depolarization (Figure 4C-D) and inward current (Figure 4 G-H). Interestingly, in the 
MSNs obtained from KO mice, the co-application of NMDA and DHPG failed to 
produce a membrane depolarization and inward current that was larger than those 
observed in the presence of NMDA alone (Fig. 4E-H). 
We then tested the effect of CDPPB on MSNs obtained from WT and KO mice, and 
as shown in Figures 4I-J, CDPPB treatment was able to recover normal NMDA 
receptor functions, which depend on mGlu5 receptor activity, in the MSNs obtained 
from Shank3 KO mice to levels comparable to those in the MSNs obtained from WT 
mice. 
 
CDPPB is able to rescue ASD-like behaviors in Shank3∆11-/- mice 
 
In our previous work we demonstrated that, in vitro, the treatment with CDPPB is 
able to restore mGlu5 reduced activity due to the knocking down of Shank3 (Verpelli 
et al., 2011). In addition, from calcium imaging analysis performed on neurons 
obtained from KO mice we found that CDPPB treatment rescues the Ca2+ transients 
to WT levels (Figure 3D). Further to these results we found that CDPPB treatment is 
able to recover normal NMDA receptor functions, which depend on mGlu5 receptor 
activity, in the MSNs of Shank3 mutant mice. 
Thus, we decided to test if behavioral deficits found in Shank3∆11-/- mice could be 
pharmacologically ameliorated treating KO mice with CDPPB. 
We evaluated the behavioral phenotypes of KO mice after treatment with CDPPB 
(3mg/kg i.p.) or vehicle (veh), which were administered acutely or repeatedly 70 min 
before each test. 
The treatment with CDPPB doesn’t affect the mice motor activity (Figure5A). 
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Acute CDPPB treatment causes a reduction of grooming time and grooming 
episodes in KO mice compared to the same genotype treated with vehicle 
(Figure5B). 
Reduced sociability (Figure 5C, left) was slightly, but not significantly, rescued in 
KO animals by acute treatment with CDPPB when analyzed as time spent close to 
the stranger/object. However, the SI, which measures sniffing activity, was 
significantly increased when the animals received CDPPB. Social recognition was 
completely rescued in Shank3∆11-/- mice, when analyzed as either the time spent 
close to the stranger2/stranger1 or sniffing activity (Figure 5C, right). 
In the water-maze place navigation task (Figure 5D), the KO mice showed normal 
acquisition compared to WT mice in terms of mean time required to reach the 
platform. A significant latency reduction between the first and the fourth trial was 
observed in all groups (Figure 5D, left), suggesting a normal progression of 
learning. During the probe test, no difference among the groups was shown in 
latency (Figure 5D, center) or the time spent in the target zone (Figure 5D, right). 
During reversal (Figure 5E), a significant difference in the escape latency across the 
trials was observed. KO mice treated with vehicle were completely impaired 
compared to their littermates, while CDPPB reduced escape latency during the 
learning phase (Figure 5E, left). 
When submitted to the probe trial on day 10, KO mice that were treated with CDPPB 
required less time to find the target zone (Figure 5E, center) and spent more time 
than the KO mice treated with vehicle to swim to the quadrant that previously 
housed the platform (Figure 5E, right). 
These pharmacological data suggest that positive allosteric modulation of mGlu5 
receptors, using CDPPB, is able to rescue the ASD-like behaviors, due to altered 
mGlu5 signaling , found in Shank3∆11-/- mice. 
 
Shank3 absence causes alterations of Homer localization in neurons derived 
from patients affected by Phelan McDermid Syndrome (PMS) 
 
Considering the limitations of mouse models and the great heterogeneity of patients 
with PMS, in terms of clinical features and size of deletions, another important model 
to study the PMS is represented by induced pluripotent stem cells (iPSCs). 
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Indeed many limitations of mouse models can be overcome with the use of iPSC 
technology, which allows the generation of personalized human neurons from 
patients. 
Donor-derived cells (e.g., dermal fibroblasts from a skin biopsy) were reprogrammed 
into iPSCs by forced expression of four pluripotency-associated transcription factors: 
OCT4, SOX2, KLF4, and c-MYC. 
In particular we established iPSC lines from two different patients with PMS, one 
with a deletion of approximately 7.99Mb (named Patient 1) and one with a deletion 
22q13.3 ARSA negative (named Patient 2). As control we used iPSCs obtained from 
two healthy donors. 
All iPSC clones were analyzed by immunofluorescence (Figure 6A) and PCR 
(Figure 6B) to test the expression of endogenous pluripotency markers. 
iPSC clones were then differentiated into cortical neurons via the generation of 
neural-rosette intermediate neural progenitors, and they were subsequently 
differentiated for 80 days. We confirmed using WB that there was a reduction in 
Shank3 protein levels in the neurons obtained from both of the PMS patients 
compared to the Shank3 levels in the controls (Figure 6C). To analyze Homer 
cluster localization, we infected neuronal progenitors with a lentivirus expressing 
Homer-GFP. Interestingly, after 80 days of differentiation, we observed a significant 
reduction in the number of Homer puncta that co-localized with Synaptophisin in 
neurons derived from both of the PMS patients compared to the co-localization 
observed in neurons derived from the controls (Figure 6D).  
These data confirm that also in human neurons, derived from patients affected by 
PMS, the absence of Shank3 causes an alteration of Homer1b/c synaptic 
localization. 
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Figure 1: Deletion of Exon 11 of SHANK3 gene causes ASD-like behaviors in 
mice 
A) Self-grooming behavior was evaluated as the time spent grooming (left) and the 
total number of grooming episodes (right). B) Differences in scores obtained for time 
spent in the chamber associated with the never seen before mouse and the empty 
cage (left) or the familiar mouse (preference for social novelty test) (right). C) Spatial 
memory was evaluated by determining a discrimination index in the spatial object 
recognition test. D-E) Acquisition and reversal in the Morris water maze was 
analyzed to determine learning patterns (left), escape latency to the target zone 
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(center) and the time spent in the quadrant (right). F) Performance in the T maze 
test was analyzed as the number of days required to reach the criterion during the 
acquisition and reversal phases. 
Data are shown as the mean ± SEM of 10 animals for each group. *, p<0.05, **; 
p<0.01; compared to the corresponding WT mice; $$, p<0.01 compared to the 
corresponding WT mice on the same day; &&, p < 0.01 compared to the same 
genotype on day 1. Student’s t-tests or two-way Anova followed by Bonferroni tests 
were used for statistical analysis. 
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Figure 2: Shank3 absence alters Homer and mGlu5 synaptic localization 
 A) Protein levels of metabotropic glutamate receptor 5 (mGlu5) and Homer1b/c 
were analyzed using Western blot analysis in postsynaptic density (PSD) fractions 
obtained from tissues in the striatum, cortex and hippocampus of wild-type (WT) and 
Shank3∆11-/- mice. Protein levels were each normalized against the respective PSD-
95 and ratios were compared between genotypes. The results are shown as bar 
diagrams, and representative blots are shown below. All data are presented as the 
mean ± SEM; all P-values were derived using unpaired, two-tailed Student’s t-tests; 
*, p<0.05; **, p<0.01. Analyses are based on a sample size of n=6 animals for each 
group (WT and KO). B) Representative confocal micrographs showing PSD-95 (red) 
and Homer1 (blue). Co-labeled puncta (arrowheads) are visible in high magnification 
images. The images show immunofluorescence puncta in the neuropil of the dorsal 
striatum, layer 2-3 of the primary somatosensory cortex and in the CA1 of the 
hippocampus in Shank3∆11-/- and KO mice. The results are shown as bar diagrams. 
Data are presented as mean ± SEM. * p<0,05; ** p<0,01. Scale bars: 5 µm and 3 
µm. C) PSD-enriched preparations of the striatum, cortex and hippocampus were 
obtained from three P60 WT and KO  mice and subjected  to an in vitro 
coimmunoprecipitation assay using rabbit Homer1b/c antibodies. The 
immunoprecipitated proteins were revealed after immunoblotting using rabbit mGlu5 
and Homer1b/c antibodies. A rabbit IgG antibody was used as the negative control. 
The data are expressed as the mean ± SEM of three independent experiments. *, p 
< 0.05. 
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Figure 3: Shank3 absence impairs mGlu5-mediated intracellular calcium 
release 
Cortical neuronal cultures were prepared from WT and Shank3∆11-/ E17-E18 mouse 
embryos. A) Western blot analysis of PSD-enriched fractions of cortical primary 
neurons obtained from WT and Shank3∆11-/- mice at DIV15. Protein levels were 
each normalized against the respective actin. Data are expressed as the mean ± 
SEM of three independent cultures by genotype. *, p < 0.05. B) At DIV14-15 
neurons were loaded with Fura-2 AM (5 µM, 30 min). After 20 min of de-
esterification, the neurons were challenged with 200 µM DHPG. The results are 
shown as bar diagrams. Representative traces of Ca2+ transients are shown on the 
left, and the data are expressed as the mean ± SEM of the indicated numbers of 
neurons that were registered from 18 coverslips (for each genotype) in three 
independent cultures. *, p < 0.05; **, p < 0.01. C) Representative images of WT and 
Shank3∆11-/- mouse primary cortical neurons at DIV15. Confocal images were 
obtained using a Confocal Microscope with a 63x objective and with sequential-
acquisition set at a resolution of 1024 x 1024 pixels. A total of 16 WT and 
Shank3∆11-/- primary cortical neurons at DIV15 were randomly chosen for 
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quantification from 4 to 10 coverslips from three independent experiments. 
Colocalization measurements were performed using MetaMorph image analysis 
software. The histogram shows the mean ± SEM for the area of Homer clusters 
(green) over the area of Bassoon clusters (blue) and the area of Homer clusters 
NOT over Bassoon clusters. *, p < 0.05. D) At DIV12-14 cortical neurons were 
loaded with Fura-2 and challenged with 200 µM DHPG either in presence (5 min 
preincubation) or in absence of of 3 µM CDPPB. Results are shown as bar 
diagrams. Representative traces of Ca2+ transients are shown left; data are 
expressed as mean ± SEM of indicated numbers of neurons registered from 18 
coverslips (for each conditions) in three independent cultures for genotype. * p < 
0.05; ** p < 0.01. 
E) Primary rat cortical neurons were prepared from E18-E19 mouse embryos at 
DIV11 and transfected with the following combinations of plasmids: GFP and FUW 
control vector (GFP+FUW); shShank3 plasmid and control FUW vector 
(shSh3+FUW); GFP and Shank3 full-length mutated to be resistant to shShank3 
(GFP+Sh3FL), and shShank3 plasmid plus Shank3 full-length (shSh3+Sh3FL). At 
DIV14-15, the neurons were loaded with Fura-2 AM (5 µM, 30 min) and stimulated 
with 200 µM DHPG. Representative traces of DHPG-induced Ca2+ transients are 
shown. F) Both GFP-expressing (transfected) and non-transduced (non-transf.) 
neurons were selected for analysis. Data are expressed as the mean ± SEM of the 
indicated numbers of neurons from 6 to 20 coverslips per condition from three 
independent culture preparations. *, p<0.05 and **, p<0.01. G) Representative 
images of rat cortical neurons that were transfected with shCtrl (control vector) and 
shShank3 constructs. In all, 6 primary rat neurons that were transfected at DIV11 
and fixed at DIV 15 for each construct were randomly chosen for quantification from 
4 to 10 coverslips from three independent experiments. Colocalization 
measurements were performed using MetaMorph image analysis software. The 
histogram shows the mean ± SEM of the area of Homer clusters (red) over the area 
of Bassoon clusters (blue) and the area of Homer clusters NOT over area of 
Bassoon clusters. **, p<0.01 
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Figure 4: The effect of mGlu5 stimulation on NMDA responses in striatal 
medium spiny neurons is dependent on Shank3 
 
Because we observed a disruption in synaptic Homer localization in the absence of 
Shank3 and high expression of Shank3 in the striatum, we tested the 
electrophysiological properties of striatal neurons. 
Patch-clamp recordings were obtained using medium spiny neurons (MSNs) 
obtained from WT and KO mice to explore whether the deletion of Shank3 affected 
the basal membrane properties of striatal neurons. Current-voltage curves were 
obtained by delivering hyperpolarizing and depolarizing steps of currents to the 
MSNs of KO (n=6) and WT (n=6) mice, and we observed no difference between 
these two groups of neurons, suggesting that the basal membrane properties of 
MSNs do not depend on Shank3 expression (Figure 4 A-B).  
We subsequently studied whether Shank3 was responsible for the observed 
changes in the membrane potential and the ionic currents induced by the stimulation 
of group I mGlu receptors in MSNs. Activation of these types of metabotropic 
glutamate receptors has been shown to enhance the membrane 
depolarization/inward current that is produced by the activation of the NMDA 
receptor in striatal MSNs. As shown in Figures 4C and 4G, the application of 30 µM 
NMDA produced a membrane depolarization of approximately 15 mV and an inward 
current of approximately -70 pA in MSNs in WT mice, while the co-application of 
NMDA in the presence of DHPG produced a significantly larger depolarization 
(Figure 4C-D) and inward current (Figure 4 G-H). Interestingly, in the MSNs 
obtained from KO mice, the co-application of NMDA plus DHPG failed to produce a 
membrane depolarization and inward current that was larger than those observed in 
the presence of NMDA alone (Fig. 4E-H). 
We then tested the effect of CDPPB on MSNs obtained from WT and KO mice, and 
as shown in Figures 4I-J, CDPPB treatment was able to recover normal NMDA 
receptor functions, which depend on mGlu5 receptor activity, in the MSNs obtained 
from Shank3 KO mice to levels comparable to those in the MSNs obtained from WT 
mice. 
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Figure 5: CDPPB is able to rescue ASD-like behaviors in Shank3∆11-/- mice 
The behavioral phenotypes of Shank3∆11-/- mice were evaluated after CDPPB (3 mg/kg 
i.p.) or vehicle (veh) treatments. Both compounds were administered acutely or 
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chronically at 70 min before each test. A) Mean horizontal (left) and vertical (right) 
movements were recorded for 10 min in an automated activity cage immediately after 
grooming recording. B) Self-grooming behaviors were evaluated as the time spent 
grooming (left) and the total number of grooming episodes (right) after acute treatment 
with CDPPB or vehicle. C) Differences in the scores corresponding to the time spent in 
the chamber associated with the never-seen-before mouse and the empty cage (left) or 
the familiar mouse (preference for social novelty test) (right). D-E) Acquisition and 
reversal tasks in the Morris water maze were performed after daily treatments for the 
duration of the task during both acquisition and reversal in mice administered CDPPB or 
vehicle to analyze learning patterns (left), escape latency to the target zone (center) and 
the time spent in the quadrant (right) during the probe test. 
The data are shown as the mean ± SEM of 10 animals for each group. *, p< 0.05; **, 
p<0.01 compared to the corresponding WT mice; $$, p < 0.01 compared to the 
corresponding Shank3 exon 11 KO mice that were treated with vehicle; #, p<0.05 and 
##, p<0.01 compared to the Shank3 exon 11 KO mice that were treated with CDPPB. &, 
p < 0.05 and &&, p < 0.01 compared to the same genotype on day 1 (two-way Anova 
followed by Bonferroni test). 
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Figure 6: Shank3 absence causes alterations of Homer localization in neurons 
derived from patients affected by Phelan McDermid Syndrome (PMS) 
A) Representative images of Ctrl and PMS derived hiPSC colonies, clones. A-B) All 
selected clones are positive for pluripotency markers as shown by 
immunfluorescence panel A and PCR panel B. C) Western blot of Shank3 protein 
expression in neurons obtained from NPC of control and PMS patients differentiated 
for 80 days. Patient 1, left; Patient 2 right. D) The panels show representative 
images of hNP-derived neurons and dendrites, which, after infection with a lentivirus 
expressing Homer-GFP, were differentiated in neuronal differentiation medium for 80 
days. The staining (right panel) shows that GFP-Homer1b clusters in iPSC-derived 
neurons colocalize with the presynaptic marker synaptophysin. The results are 
shown as bar diagrams. The data are presented as the mean ± SEM. *, p<0.05.  
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Phelan-McDermid (PMS or 22q13.3 deletion syndrome) syndrome is a rare genetic 
disorder that causes a severe form of intellectual disability (ID), expressive language 
delays and other autistic features. 
PMS results from the loss of the distal long arm of chromosome 22, in particular the 
22q13.3 region. 
The chromosome 22 breakpoint is located precisely within the exon 21 of the human 
homologue of the ProSAP2 gene, SHANK3, and it has been demonstrated that the 
majority of 22q13.3 deletion syndrome neurological deficits are related to 
haploinsufficiency of SHANK3 gene. 
Furthermore SHANK3 truncating mutations have been reported in patients with 
autism spectrum disorders (ASD) (Moessner et al., 2007, Nemirovsky et al., 2015, 
Hara et al., 2015, Cochoy et al., 2015). ASDs are a group of neurodevelopmental 
disorders including autism, Asperger syndrome, childhood disintegrative disorder, 
and pervasive developmental disorder not otherwise specified (Liu and Scott, 2014). 
ASD is defined by two main behavioral features: repetitive/restricted behavioral 
patterns and impaired sociability and communication. 
Considering the relevant role of Shank3 in these disorders, the study of Shank3 
function in the brain is crucial to identify new pharmacological targets for treating 
patients affected by SHANK3 mutations or deletions. 
For this reason in the last years seven Shank3 KO mouse models have been 
generated, deleting different regions of the gene (Peça et al., 2011, Schmeisser et 
al., 2012, Bozdagi et al., 2010, Wang et al., 2011, Kouser et al., 2013, Lee et al., 
2015). 
Shank3 is one of the most important scaffolding proteins at postsynaptic density of 
excitatory synapses. Thanks to its multiple domains is able to connect each other a 
large number of proteins including other scaffolding proteins, actin-binding proteins 
and glutamate receptors. 
For this reason Shank3 plays an important role in the proper establishment and 
maintenance of synaptic contacts and plasticity. 
 
To study the role of Shank3 in synapse function and to develop therapies that might 
ameliorate the neuropsychiatric symptoms found in  patients with PMS or other 
mutations in the SHANK3 gene, we characterized the behavioral, molecular and 
electrophysiological phenotypes of Shank3 mutant mice that were generated by 
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deleting the exon 11 (Schmeisser et al., 2012). Among the Shank3 mutants that 
were available, Shank3∆11-/- mice are less often studied, although they are highly 
homologous to the Shank3B-/- mutants, lacking the PDZ domain described by Peça 
et al. (Peça et al., 2011). 
 
From the behavioral analyses we found that Shank3∆11-/- mice present an increased 
self grooming behavior and impaired social interaction, so the two main features of 
ASD, suggesting that this is a good model to study the role of Shank3 in the 
pathogenesis of PMS and ASD. 
 
Shank proteins interact with group I of metabotropic receptors, which includes 
mGlu5, through the binding to Homer1 scaffold proteins. 
We focused our attention on the analysis of mGlu5 and Homer protein levels, 
because our previous data showed a reduce expression of mGlu5 in Shank3 knock-
down neurons (Verpelli et al., 2011). In Shank3∆11-/- mice we found a reduction of 
the protein expression levels of mGlu5 and Homer1b/c in cortex and striatum.  
Our biochemical and morphological data demonstrate that in Shank3∆11-/- mice, the 
localization of Homer1b/c to the PSD is significantly reduced in two different brain 
areas: striatum and cortex. This lead to a consequent reduction of the synaptic 
association between Homer1b/c and mGlu5 in these specific brain regions. 
 
The reduction of Homer expression is a common alteration found in different Shank3 
mutants (Wang et al., 2011, Peça et al., 2011). 
In addition our data indicate that Shank3 in different brain regions could have 
different functions at synapses. 
This brain-region specificity of Shank3 in regulating glutamate receptor levels at 
synapses, have been observed also in other Shank3 mutant mice (Wang et al., 
2011, Peça et al., 2011), suggesting that splice variants have a crucial role in this 
process.  
Shank3 is important for Homer1b/c clustering at synapses also in human neurons, 
indeed we demonstrated that Homer1b/c cluster formation is impaired in hiPSC-
derived neurons obtained from patients affected by PMS, suggesting that Shank3 is 
also important for the normal clustering of Homer1b/c into synaptic puncta in human 
neurons. 
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Homer physically and functionally links mGlu5 receptors to their downstream 
effectors, the IP3 receptors, allowing a more efficient release of intracellular calcium 
in response to receptor stimulation, so Homer-mGlu5 complex formation is 
necessary for the correct functionality of mGlu receptors (Ronesi et al., 2012). 
We demonstrated in vitro that mGlu5-dependent Ca2+ release from intracellular 
stores is impaired in cortical neurons obtained from Shank3∆11-/- mice and we 
further provided in vivo data in which mGlu5-dependent NMDA receptor potentiation 
is completely abolished in striatal medium spiny neurons of Shank3∆11-/-  mice. 
The importance of Shank3 in regulating mGlu5 signaling is also supported by the 
fact that the expression of shRNA-resistant Shank3 rescued the changes in DHPG-
induced Ca2+ release from intracellular stores observed in Shank3 knocked down 
cortical neurons. 
We also provided the evidences that CDPPB induced the positive modulation of 
mGlu5 activity and rescued the functional deficits observed in both cortical and 
striatal neurons in Shank3∆11-/- mice. 
Taken together these data demonstrate that the absence of Shank3 causes 
principally an alteration of group I mGlu receptors mediated synaptic signaling in 
specific brain areas. 
 
Recent studies reported that the inhibition of mGlu-Homer complex formation 
impairs mGlu receptors-dependent LTD and protein synthesis in normal mice 
(Ronesi et al., 2012). 
In a mouse model of Fragile- X syndrome, mGlu5 receptors are less associated with 
Homer1b/c and more associated with Homer1a (Giuffrida et al., 2005, Ronesi et al., 
2012), that interferes with the cross-linking activity of Homer1b/c (Hayashi et al., 
2009). 
Similarly, in a mouse model of Angelman Syndrome, mGlu5 receptor-dependent 
synaptic plasticity was altered because it showed an increased association with 
Homer 1b/c (Pignatelli et al., 2014). 
In these two models an enhancement of hippocampal mGlu5 receptor function is the 
main phenotype, while in our mouse model is exactly the opposite, indeed we 
observed a decrease of mGlu5 receptor function. 
This indicates that if mGlu5 signaling is pathologically modified in any direction 
(enhancement or reduction) this causes an alteration of synapse function. 
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Recently it has been also identified HOMER1 as a novel risk gene for non-syndromic 
ASD (Kelleher et al., 2012) and it has been showed that mGlu5 gene expression is 
reduced within the dorsolateral prefrontal cortex of ASD patients (Chana et al., 
2015). 
Because all our findings underlined and confirmed a critical impairment on Shank3-
Homer-mGlu5 complex, we decided to test if ASD-like behaviors of Shank3∆11-/- 
mice can be reversed by the treatment with CDPPB, an allosteric positive modulator 
of mGlu5. 
The, in vivo, treatment with CDPPB is able to rescue repetitive behavior, cognitive 
rigidity and partially social interaction. 
Importantly the potential of mGlu5 PAM has already been tested in other models of 
ASD. Indeed CDPPB restored synaptic and behavioral deficits in mouse models of 
tuberosclerosis syndrome (TSC), a genetic syndrome associated to ASD and ID 
(Auerbach et al., 2011), and very recently CDPPB administration ameliorated the 
behavioral deficits reported in Sarm1 knockdown mice (Lin et al., 2014).In addition in 
a mouse model lacking  exon 4-6 of SHANK2 gene, that presents ASD-like 
phenotypes, the treatment with CDPPB normalized some behavioral deficits (Won et 
al., 2012). 
Our data show that the use of a positive allosteric modulators of mGlu5, such as 
CDPPB, antagonizes ASD-like behaviors and suggests that mGlu5 activity could be 
envisaged as a potential therapeutic target for neurodevelopmental disorders in 
general, as suggested by many recent studies (Nickols and Conn, 2014). 
 
Concluding in our work we demonstrated that the deletion of exon 11 of SHANK3 
gene in mice leads to ASD like behaviors and that in this mouse model Shank3 
plays a major role in modulating mGlu5 signaling by regulating Homer 
recruitment/localization to the PSD specifically in cortex and striatum, two brain 
regions that are highly associated to ASD-like behaviors. 
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